Solving the AAV Puzzle: A New Focus on Gene Therapy Design for Vision

CHICAGO, IL – April 30, 2026 – As the promise of gene therapy for debilitating eye diseases grows, a leading company is shifting the industry’s focus from celebrating early wins to solving the stubborn technical problems that limit their widespread success. VectorBuilder, a global leader in gene delivery, will take the stage at the upcoming Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting to address the critical challenges of consistency and scalability in Adeno-Associated Virus (AAV) therapies.

The presentation signals a maturing field, moving beyond initial breakthroughs to confront the foundational issues that determine whether a promising therapy can become a reliable, accessible medicine. For patients with genetic forms of blindness, the outcome of this effort could mean the difference between a temporary reprieve and a lasting cure.

The High Stakes of AAV Inconsistency

AAV has become the workhorse vector for in-vivo gene therapy, particularly in ophthalmology, due to its strong safety profile and ability to deliver genetic payloads to specific cells in the eye, as demonstrated by the landmark approval of Luxturna. However, as more AAV-based therapies enter clinical trials, the industry is grappling with persistent variability in their performance.

Key among these challenges is immunogenicity. A significant portion of the population has pre-existing antibodies to AAV, which can neutralize the therapeutic vector before it reaches its target. Even without pre-existing immunity, the introduction of high doses of viral vectors can trigger an immune response, potentially destroying the very cells the therapy is meant to fix and preventing any future re-dosing. A major contributor to this problem is the high concentration of “empty capsids”—AAV particles that contain no therapeutic DNA but still contribute to the overall viral load and can provoke an immune reaction. Regulatory bodies like the FDA are increasingly focused on this issue, recommending strict limits on empty capsids to improve product safety.

Beyond the immune response, manufacturing itself remains a significant bottleneck. Scaling up production from small lab batches to the commercial quantities needed to treat thousands of patients is fraught with difficulties, including low yields and process variability. This lack of standardization across the industry means that therapies developed by different companies can have widely varying characteristics, complicating regulatory review and clinical outcomes. Research has shown that in ocular gene therapy trials, the rate of sustained clinical benefit can be lower than in other areas, highlighting a specific need to improve the durability of these treatments for the eye.

Re-Engineering the Blueprint for Gene Delivery

At the ARVO meeting in Denver, VectorBuilder’s CDMO for Global Operations, Alan Griffith, will present “Seeing Old Problems in a New Light: Unlocking the Full Potential of AAV-Based Therapies.” The session aims to re-center the conversation on the most fundamental aspect of the process: the initial design of the vector itself.

“AAV has become a cornerstone of gene therapy development, particularly in ophthalmology, but its full potential depends on how consistently it can be designed and produced,” Griffith stated in a press release. “Revisiting long-standing assumptions around vector design is essential to improving reliability and translating early success into broader clinical impact.”

This philosophy is the bedrock of VectorBuilder’s approach. The company has invested heavily in tools like its online Vector Design Studio, which allows researchers to meticulously plan and optimize every component of their gene delivery vehicle before it is ever produced. By addressing potential issues at the blueprint stage, the company aims to prevent costly failures downstream. This includes engineering novel AAV capsids—the outer protein shell of the virus—to enhance targeting of specific retinal cells, improve transduction efficiency, and even evade the immune system. The development of specialized “ocular capsids” that demonstrate superior penetration of the retina is a direct result of this design-first strategy.

From Bespoke Science to Standardized Medicine

The push for better design and consistency is part of a larger industry-wide movement to professionalize gene therapy manufacturing. As these complex biological drugs move toward commercialization, the role of specialized Contract Development and Manufacturing Organizations (CDMOs) has become indispensable. These organizations provide the expertise and infrastructure necessary to produce gene therapies under the stringent Good Manufacturing Practice (GMP) standards required by regulators.

The AAV CDMO market is a competitive space, with major players like Catalent, which has produced FDA-approved AAV therapies, and Charles River Laboratories, which acquired Vigene Biosciences to bolster its gene therapy capabilities, all vying to offer faster and more reliable manufacturing platforms. This competition is driving innovation aimed at solving the exact scalability and quality-control issues that have plagued the field. By establishing robust, repeatable processes and comprehensive quality control assays, companies like VectorBuilder are working to transform gene therapy from a bespoke, lab-based art into a standardized, industrial science.

This standardization is crucial for ensuring that every vial of a therapy is safe, pure, and potent. It gives regulators confidence in the product and provides clinicians and patients with assurance that the treatment will perform as expected, a critical step for building trust in this revolutionary class of medicines.

A Clearer Horizon for Patients

Ultimately, these technical advancements in vector design and manufacturing have a profound human impact. For the millions of people worldwide affected by inherited retinal diseases and other genetic ocular conditions, progress in the AAV field offers tangible hope. A more reliable and durable AAV platform could expand the number of treatable diseases and improve long-term outcomes for existing ones.

By engineering vectors that are more efficient at delivering their genetic payload, developers may be able to use lower doses, significantly reducing the risk of adverse immune reactions. Likewise, creating vectors that can better evade the immune system could make treatments effective for a larger portion of the patient population and potentially allow for re-administration if the therapeutic effect wanes over time. The successful translation of these improvements from the lab to the clinic could accelerate the development pipeline for therapies targeting conditions like retinitis pigmentosa, Leber congenital amaurosis, and even more common diseases like wet age-related macular degeneration.

VectorBuilder's focus at the ARVO meeting underscores a pivotal moment for genetic medicine. By tackling the foundational, and often unseen, challenges of vector production, the industry is laying the groundwork for a future where gene therapies are not just groundbreaking scientific achievements, but dependable and transformative treatments for patients facing the loss of their sight.